RPTX vs. OCGN, INMB, GNFT, FULC, NLTX, CYBN, SLRN, MDWD, IVVD, and PLX
Should you be buying Repare Therapeutics stock or one of its competitors? The main competitors of Repare Therapeutics include Ocugen (OCGN), INmune Bio (INMB), Genfit (GNFT), Fulcrum Therapeutics (FULC), Neoleukin Therapeutics (NLTX), Cybin (CYBN), Acelyrin (SLRN), MediWound (MDWD), Invivyd (IVVD), and Protalix BioTherapeutics (PLX). These companies are all part of the "pharmaceutical products" industry.
Repare Therapeutics vs.
Repare Therapeutics (NASDAQ:RPTX) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, community ranking, earnings, risk and institutional ownership.
Repare Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.82, meaning that its share price is 282% more volatile than the S&P 500.
Repare Therapeutics currently has a consensus target price of $7.00, suggesting a potential upside of 442.64%. Ocugen has a consensus target price of $6.00, suggesting a potential upside of 782.35%. Given Ocugen's stronger consensus rating and higher probable upside, analysts plainly believe Ocugen is more favorable than Repare Therapeutics.
In the previous week, Ocugen had 6 more articles in the media than Repare Therapeutics. MarketBeat recorded 7 mentions for Ocugen and 1 mentions for Repare Therapeutics. Ocugen's average media sentiment score of 1.24 beat Repare Therapeutics' score of 0.00 indicating that Ocugen is being referred to more favorably in the news media.
Ocugen has lower revenue, but higher earnings than Repare Therapeutics. Ocugen is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks.
Ocugen received 69 more outperform votes than Repare Therapeutics when rated by MarketBeat users. Likewise, 70.70% of users gave Ocugen an outperform vote while only 63.64% of users gave Repare Therapeutics an outperform vote.
Repare Therapeutics has a net margin of -99.76% compared to Ocugen's net margin of -532.51%. Repare Therapeutics' return on equity of -40.87% beat Ocugen's return on equity.
85.1% of Repare Therapeutics shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 21.6% of Repare Therapeutics shares are held by company insiders. Comparatively, 4.3% of Ocugen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Ocugen beats Repare Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Repare Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Repare Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RPTX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free RPTX Stock Alerts